search
for
 About Bioline  All Journals  Testimonials  Membership  News


Indian Journal of Dermatology, Venereology and Leprology
Medknow Publications on behalf of The Indian Association of Dermatologists, Venereologists and Leprologists (IADVL)
ISSN: 0378-6323 EISSN: 0973-3922
Vol. 73, Num. 6, 2007, pp. 423-423

Indian Journal of Dermatology, Venereology and Leprology, Vol. 73, No. 6, November-December, 2007, pp. 423

Letter To Editor

Imiquimod-induced vitiligo-like depigmentation

Engin Senel, Deniz Seçkin

Baskent University Faculty of Medicine, Department of Dermatology, Ankara
Correspondence Address:Department of Dermatology, Baskent University Faculty of Medicine, 5. sokak No: 48 Bahcelievler, Ankara-06490
enginsenel@yahoo.com

Code Number: dv07159

Sir,

Imiquimod, an imidazoquinoline amine, is a potent topical immune response modifier. [1] It has been used effectively to treat human papillomavirus-induced warts, molluscum contagiosum, actinic keratoses and superficial basal cell carcinoma. [2]

A 32 year-old man presented to our clinic with genital warts, which had been present for the last six months. Dermatologic examination revealed multiple verrucous papules on the shaft of the penis and pubic area and depigmented macules on the glans penis, the shaft of the penis and the scrotum [Figure - 1]. Imiquimod 5% cream had been applied to the warts every other night. After two months, he had noticed erythematous lesions on the dorsal surface of the penis and the scrotum. These lesions turned into depigmented areas in three months. Depigmentation never extended to the areas that had not been treated with imiquimod. No repigmentation was noted in a six-month follow-up period. The patient had no personal or family history of vitiligo.

Imiquimod is generally a well-tolerated drug. Its most frequent side effects are erythema, flaking, scabbing, edema and excoriation. In addition, only two cases of depigmentation caused by imiquimod have been reported. [3],[4] The authors speculated that imiquimod might have acted as a triggering factor in a susceptible patient who had a positive family history of vitiligo. [4] They also suggested that clinicians should be cautious when prescribing imiquimod in patients with a personal of family history of vitiligo. [4] However, our patient and the other reported case had no personal or family history of vitiligo.

Imiquimod enhances antigen presentation by stimulating CD8+ T cell activation and inducing Langerhans cell maturation. [5] Vitiligo-like depigmentation may result from the destruction of melanocytes by CD8+ T cells directed to melanocyte surface antigens after antigen presentation is enhanced by imiquimod.

Dermatologists should be aware of this possible side effect of imiquimod, which may be long-lasting or irreversible.

References

1.Rudy SJ. Imiquimod (Aldara): Modifying the immune response. Dermatol Nurs 2002;14:268-70.  Back to cited text no. 1  [PUBMED]  
2.Majewski S, Marczak M, Mlynarczyk B, Benninghoff B, Jablonska S. Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis. Int J Dermatol 2005;44:14-9.  Back to cited text no. 2  [PUBMED]  [FULLTEXT]
3.Brown T, Zirvi M, Cotsarelis G, Gelfand JM. Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts. J Am Acad Dermatol 2005;52:715-6.  Back to cited text no. 3  [PUBMED]  [FULLTEXT]
4.Stefanaki C, Nicolaidou E, Hadjivassiliou M, Antoniou C, Katsambas A. Imiquimod-induced vitiligo in a patient with genital warts. J Eur Acad Dermatol Venereol 2006;20:755-6.  Back to cited text no. 4  [PUBMED]  [FULLTEXT]
5.Eedy DJ. Imiquimod: A potential role in dermatology? Br J Dermatol 2002;147:1-6.  Back to cited text no. 5  [PUBMED]  [FULLTEXT]

Copyright 2007 - Indian Journal of Dermatology, Venereology and Leprology


The following images related to this document are available:

Photo images

[dv07159f1.jpg]
Home Faq Resources Email Bioline
© Bioline International, 1989 - 2024, Site last up-dated on 01-Sep-2022.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Google Cloud Platform, GCP, Brazil